Jerry Sweeney
Analyst · Bank of America
Olivia, thank you very much. Good morning, everyone, and thank you for participating in our second quarter 2021 earnings call. On today’s call with me are George Johnstone, our Executive Vice President of Operations; Dan Palazzo, our Vice President and Chief Accounting Officer; and Tom Wirth, our Executive Vice President and Chief Financial Officer. Prior to beginning today’s call, I just want -- certain information we discuss during this call may constitute forward-looking statements within the meaning of the federal securities law. And although we believe estimates reflected in these statements are based on reasonable assumptions, we cannot give assurance that the anticipated results will be achieved. For further information on factors that could impact our anticipated results, please reference our press release as well as our most recent annual and quarterly reports that we file with the SEC. So first and foremost, we hope that you and yours continue to be safe, healthy and engaged as we return the economy to normal. And while certainly the COVID-19 situation remains volatile with daily news breaking, there is much more optimism among our tenants as the economy trends towards a full reopening. We’re hearing that directly from both large and small tenants. Our portfolio occupancy as of late June increased to approximately 33%, which represents a significant increase from where we were in April, where we reported between 15% and 20% occupancy levels. The predominance of tenants returning has expanded beyond just small employers as occupancy for tenants 50,000 square feet and below is over 45%. During our comments today, we’ll review our second quarter results, discuss progress on our 2021 business plan and update all of you on our recent capital activity. Tom will then provide a financial overview. After that, Dan, Tom, George and I are available for any questions. First, just a general update on the COVID-19 impact on our business. As previously noted on earlier calls, each building of ours has a customized return-to-workplace presentation, and our property teams are doing an excellent job guiding our tenants to return to a safe work environment. Based on an updated tenant survey that was completed in late June, we found a couple of interesting things. First, there’s a growing need for space planning services which, as we expected, is I think a good sign. 48 tenants representing about 1.2 million square feet have requested assistance from our internal space planning team, and we have engaged with them. We also got a lot of feedback on an increased need for parking due to near-term public transportation concerns, which we certainly believe are short term in duration. But about 103 of our tenants representing almost 3 million square feet expressed an interest in parking. And actually, during the quarter, we entered into 167 new monthly contracts and saw a 30% increase in our parking lot occupancies. From a portfolio management standpoint, we’ve been very much focused on tenants whose spaces expire in the next 2 years. Those efforts have been successful. We have reduced our forward rollover exposure to an average of 6% over the next 3 years. And as noted on Page 2 of our sup, to 7.1% from ‘22 to ‘24. So our forecasted rollover exposure is below 10% annually in each year through 2026. So over the last several quarters, we have significantly improved our intermediate term portfolio stability. Revenue and earnings growth remain a top priority. We do believe we have some key near-term earnings drivers. First, we have, as you all know, some several key vacancies that upon lease-up over the next 8 quarters will generate between $0.07 and $0.10 of additional revenue per share. That is in both our wholly owned and joint venture inventory. We are also projecting that 405 Colorado and 3000 Market stabilize in 2022 as we bring those development projects online. And we’re seeing clear trend lines of tenants requiring higher quality space, which we believe positions our portfolio extremely well. And that’s really evidenced by what we’re hearing, but also by a 23% increase in our development pipeline Q2 over Q1. And looking at the numbers for the second quarter, we posted FFO of $0.32 per share, which was in line with consensus estimates. We made excellent progress on all of our 2021 business plan metrics. And during the quarter, we had 20,000 square feet of positive absorption. Given increased leasing visibility through the balance of the year, we did increase our speculative revenue target by -- midpoint by $500,000 and reduced the range -- narrowed the range, rather, from $18 million to $22 million to $20 million to $21 million. And as reported, we are now 98% complete at that revised range. Rent collections continue to be very strong and one of the best in the sector as we’ve collected over 99% of our second quarter rents. Our July receipts continue to track towards that same level. Tenant retention was 58%. Our lease percentage remains within our business plan range. Second quarter capital costs were 12.8% of generated revenues, slightly above our 10% to 12% business plan range. Our average lease term was 8.5 years, which exceeded our 7-year business plan target. Cash mark-to-market was a positive 14% and our GAAP mark-to-market was also positive 22%. All of those results were above our full year published ranges. However, as we mentioned last quarter, based on leases already executed and commencing later this year with lower mark-to-market results, we will be within our business plan ranges. We also expect that every region will post positive mark-to-market results on both a cash and GAAP basis for 2021. Our second quarter GAAP same-store NOI was 0.5%, and year-to-date is below our 2021 range of 0% to 2%. Second quarter cash same-store NOI was 1.8%, again, below our 2021 range of 3% to 5%. Again, very similar to the mark-to-market dynamics. Tenants scheduled to take occupancy later this year will accelerate same-store growth and enable us to achieve our ‘21 business plan range. With the exception of our Met DC operation, all of our regions are expected to post positive same-store results, and our Met DC region will remain negative, while 1676 International continues through its lease-up phase. We are still forecasting ‘21 year-end debt-to-EBITDA in the range of 6.3 to 6.5. As we’ve always cautioned, that does depend on the timing of future development starts for the balance of the year. And just a couple of comments on leasing velocity because I know everyone is looking for recovery data points, just like we are. And we think there are some encouraging signs, at least what we’ve seen in the last quarter. A lot of tenant prospects with the pandemic want to virtually tour spaces before committing to an in-person tour. We continue to see this trend evolve during the quarter. We had a total of over 1,500 virtual tours with almost 800,000 square feet being targeted. That led to a 46% increase in physical tours over Q1. Our overall pipeline stands at 1.4 million square feet with approximately 200,000 square feet in advanced stages of lease negotiations. Our overall pipeline increased by just shy of 600,000 square feet during the quarter. And while these recovery points are encouraging, we do believe it will take several quarters to assess the full impact on the office business from the pandemic. So to gain some insight, we looked at our leasing metrics from the second quarter of 2019, so pre-pandemic, same quarters we’re in now. Those data points we thought were also encouraging. On a comparable set of properties, the pipeline today is up 7% compared to the second quarter of 2019. Leases that we executed this quarter are also up 13% from the second quarter of ‘19. Deals at the proposal stage are up 20%, including new and expansion proposals being up 13% over that comparative period. There are 2 additional benchmarks we looked at that demonstrate that we’re clearly still in the recovery phase. But overall, we’re surprisingly good compared to the second quarter of 2019. Our deal conversion rates, it was down 6% to 28% in the second quarter of ‘21 versus 34% in the second quarter of ‘19. And as you might expect, given where we are in this recovery phase, the medium deal cycle time is up 27 days to 104 days this past quarter versus 77 days in the second quarter of ‘19. So we’re hoping that as the economy continues to open, we’ll see condensing of that deal cycle time as that’s really is where the rubber meets the road in terms of revenue generation. In looking at liquidity, we have excellent liquidity, anticipate having $460 million of line of credit availability by the end of the year. As Tom will touch on, we have no unsecured bond maturities until 2023 and have a fully unencumbered wholly owned asset base. Our dividend is extremely well covered at 57% of FFO and 81% of CAD at the midpoint of our guidance. Our 5-year dividend growth rate has been 5.3% versus a peer average below 4%. And we have grown our CAD during that same 5-year period, close to an 8% annual rate versus a peer average again below 4%. From a capital allocation standpoint, it was a fairly quiet quarter. We continue to make progress on many fronts. And subsequent to quarter end, as part of our land recycling program, we did sell 2 small noncore land parcels and posted a small gain on that. Looking at development. As we always note, we have a number of production development projects that can be completed in 4 to 6 quarters that cost between $40 million and $70 million. The pipeline on those 4 production assets grew 40% since the first quarter, which is a good sign, again, I think, of tenants entering the market, but also looking for high-quality space. And along those lines, we did start the renovation program for 250 King of Prussia Road. That is a 169,000 square foot project located in the Radnor submarket that we acquired for approximately $120 per square foot as part of an overall transaction with Penn Medicine. We’ve designed that project to accommodate a significant life science component. The renovation started in the second quarter, and will be wrapped up within the next 4 quarters. This project will be the first component of our Radnor Life Science Center, which will initially consist of this project and our planned 155 Radnor ground-up 150,000 square foot development. And these 2 projects will deliver more than 300,000 square feet of life science and office space to one of the region’s best performing long-term submarkets. And looking at the existing development projects, Schuylkill Yards West is very much on pace and on schedule. That’s a life science residential and office project we commenced on March 1. The project will be built with 7% blended yield and consists of 326 apartment units, 100,000 square feet of life science space, 100,000 square feet of innovative office space and street-level retail. Still have an active pipeline comparable to last quarter. We did close our 65% loan-to-cost construction loan at a floating rate equal to 3.75%. However, given the front load of the equity commitment for both us and our partner, even with Brandywine’s $55 million equity commitment, of which $46.5 million is already invested, the first funding of that construction loan won’t occur until first quarter of ‘22, but it does complete the capital stack for that project. Looking at our 405 Colorado project in Austin, that project is now complete. We’re scheduling a grand opening in the fall. During the quarter, our lease percentage did increase to 24%, and we currently have a pipeline of 527,000 square feet, including about 40,000 square feet in final lease negotiations. 3000 Market is our life science renovation within Schuylkill Yards. That project is fully leased. The construction will finish later this year, and we’re projecting the lease commencing fourth quarter ‘21 at a development yield of 9.6%. Cira Labs, which we announced last quarter, is a 50,000 square foot incubator that we are partnering with Pennsylvania Biotechnology Center. B.Labs will open in the fourth quarter of ‘21. Since the announcement, we have entered the marketing pipeline and had built a significant amount of interest with proposals outstanding for roughly 78% of that space. Just have a couple more updates on Schuylkill Yards and Broadmoor. Within Schuylkill Yards, the life science push continues. As we’ve cited previously, we can deliver about 3 million square feet of life science space, which we believe creates an excellent opportunity to establish a corollary research community to all the other great activity over here in University City. 3151 Market Street, our dedicated life science building, is fully designed and ready to go. We have a leasing pipeline on that still in the 400,000 square foot range. It is advancing, advancing slowly, but I think with a high degree of confidence. And our goal remains being able to start that later this year, assuming market conditions permit. At Broadmoor, we are progressing with Block A and the first phase of Block F. To recap, the scope of that is 350,000 square feet of office and 613 apartment projects at a total cost of about $367 million. We are in a go mode on all those components. We are moving forward through final documentation with our selected equity partner on Block A and Block F residential and are soliciting bids now on construction financing alternatives. We anticipate a third quarter closing date on both Blocks A and F. Our plan remains to start the residential component of Block A, which is 341 units at $119 million cost in the fourth quarter of ‘21. And on Block A office, we are actively in the pre-leasing market, and we plan to start that as market conditions permit. Just one final note before I turn the call over to Tom to review financial results, and it relates to our third quarter earnings cycle. As you may recall, we would normally provide ‘22 earnings and business plan and FFO guidance during our third quarter ‘21 earnings cycle. However, consistent with what we said we did in ‘21 and based on the continued uncertain business climate, we will announce our ‘22 guidance on our fourth quarter earnings call. So Tom will now provide a review of our financial results.